All FDA-approved drugs have what is known as prescribing information—a document that provides a comprehensive listing of information doctors need to know in order to safely and effectively prescribe the drug. This includes information on which conditions the drug has been approved to treat, its efficacy, possible side effects, drug interactions, precautions and warnings for certain patients, dosing and administration, and a detailed list of ingredients.
Although the prescribing information is intended for healthcare providers, there is no better source for detailed information about FDA-approved drugs. For this reason, patients who want more detailed clinical information will often consult the prescribing information.
Prescribing Information for Sandostatin® LAR Depot (octreotide acetate for injectable suspension)
The safety and efficacy of Sandostatin® LAR Depot (octreotide acetate for injectable suspension) for treating acromegaly, carcinoid syndrome, and VIPomas was established in clinical trials. Keep in mind as well that Sandostatin® LAR Depot is a reformulation of a trusted, reliable treatment that has been used worldwide for 10 years in thousands of patients—immediate release Sandostatin® (octreotide acetate) Injection. Both share the same active ingredient, octreotide acetate.
Read the full Prescribing Information for Sandostatin® LAR Depot
Read the full Prescribing Information for immediate release Sandostatin® Injection
Important Safety Information
Carcinoid Syndrome:
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported.
The controlled clinical trials that support the marketing clearance for Sandostatin® LAR Depot did not include determination of effect on tumor size or rate of growth. Sandostatin® LAR Depot is not indicated for tumor shrinkage. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Acromegaly
Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal.
Important Safety Information:
As with immediate release Sandostatin® Injection, the most frequently reported drug-related adverse events were biliary disorders (52%), gastrointestinal disorders (7% to 36%), and injection-site pain (2% to 11%). Hypoglycemia (2%), hyperglycemia (15%), and hypothyroidism (2%) have been reported. While not measured in acromegalic patients receiving Sandostatin® LAR Depot, ECG changes have been reported in patients receiving immediate release Sandostatin® Injection; the degree to which these abnormalities are related to octreotide acetate is not clear, as many acromegalics have cardiovascular disease. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
